Literature DB >> 25462134

Micelle-assisted combination therapies for effective glioblastoma treatment: an in-vitro assessment.

Anjan Kumar Mohanty1, Guru Prasad Mohanta.   

Abstract

Glioblastoma is the most fatal type of brain tumor, requiring a better chemotherapy regime to prolong the survival of the patient. The toxicity associated with a high dose of a single drug can be overcome by a combination of different anticancer drugs. Methoxy poly(ethylene glycol)-poly (ε-caprolactone) block copolymeric micelles loaded with two different anticancer drugs such as curcumin and rapamycin were used to assess their therapeutic efficacy in glioblastoma cell lines. In addition, the combination of curcumin and rapamycin was also encapsulated in micelles for better anticancer activity. The in-vitro cellular uptake studies and cytotoxicity studies showed that the drugs encapsulated in the micelles showed ∼3.3 times more uptake than a mixture of native drugs as well as a single drug. The enhanced mitochondrial membrane potential depolarization by drug-loaded micelles leads to higher cell death compared with native drugs in T98G glioblastoma cell culture experiments. The drug combination downregulates P13/AKT and serine/threonine kinase proteins, and leads to programmed cell death. Thus, curcumin and rapamycin-loaded micelles can be used effectively for the treatment of glioblastoma.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25462134     DOI: 10.1097/CAD.0000000000000186

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  2 in total

Review 1.  Curcumin in Combination with Other Adjunct Therapies for Brain Tumor Treatment: Existing Knowledge and Blueprint for Future Research.

Authors:  Kavita Peter; Santosh Kumar Kar; Ragini Gothalwal; Puneet Gandhi
Journal:  Int J Mol Cell Med       Date:  2022-01-10

Review 2.  Nano-drug co-delivery system of natural active ingredients and chemotherapy drugs for cancer treatment: a review.

Authors:  Bingqian Li; Huili Shao; Lei Gao; Huan Li; Huagang Sheng; Liqiao Zhu
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.